Sirius licenses sepsis markers to Tm Bioscience
This article was originally published in Clinica
Executive Summary
Molecular test developer Tm Bioscience has excusively licensed from fellow Canadian company Sirius Genomics specific biomarkers associated with drugs used for treating severe sepsis. Toronto-based Tm Bioscience will incorporate these markers into a test that identifies patients who would respond well to vasopressin and Xigris, the two drugs commonly used to treat the condition. The product, scheduled for launch in the second half of 2007, is expected to generate sales of over US$100m in the first three years of commercialisation.
You may also be interested in...
California Bill To Age-Restrict Sales Of Diet Pills Further Along Than Other States’ Legislation
CA, MA and NJ legislatures remain in session with bills active proposing regulations similar to NY law effective 22 April requiring retailers, including online, to ask for proof of age when customers buying consumer health products containing ingredients labeled or promoted for weight loss and bodybuilding benefits appear younger than 18.
CRN Has Standing For Steep Hill To Climb Challenging New York's Age-Restricted Sales
Federal judge finds “misreading of the legislation” in CRN’s argument that state “restricts access based purely on what has been said about the product or its ingredients.” But standing to challenge “means that only CRN is positioned right now to go before the court on behalf of industry,” says CEO Steve Mister.
Addition to Quest Alzheimer's Suite Looks For Biomarker P-Tau217
The test is being integrated into Quest’s AD-Detect portfolio for assessing the risk of Alzheimer’s. It is the third p-tau217 test to make news this month, after new breakthrough designations for Quanterix and Roche and Eli Lilly.